Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Results filtered:Study status:
Contact Us for the Latest Status
Closed for Enrollment
The study proposes to form a consortium of autoimmunity of the optic nerve with the goal of improving diagnosis and treatment of these conditions.
Investigators will compare magnetic resonance (MR) elastography and/or ultrasound elastography measurements to other forms of noninvasive methods of detecting raised intracranial pressure, including optical coherence tomography (OCT) imaging measurements of the retinal nerve fiber layer (RNFL) and indirect signs of raised intracranial pressure on magnetic resonance imaging (MRI).
The purpose of this study is to determine if optical coherence tomography (OCT) angiography is able to distinguish different causes of optic neuropathy.
The purpose of this study is to evaluate the clinical utility of a quantitative test to measure how color saturation appears in patients with diseases of the optive nerve.
This study will determine the effect of QPI-1007 on visual function in subjects with recent-onset NAION and assess the safety and tolerability of intravitreal injections of QPI-1007 in this population. This study will also evaluate the structural changes in the retina following administration of QPI-1007.
The purpose of this study is to explore the various retinal modalities to determine if they may provide a non-invasive method of identifying populations at risk for developing Alzheimer’s Disease (AD) and predict disease progression.
The goal of this study is to evaluate the efficacy of the critical flicker fusion device in distinguishing different kinds of optic neuropathy.
The goal of this study is to evaluate the efficacy of B-scan ultrasonography in identifying increased ICP in patients with idiopathic intracranial hypertension via measurement of optic nerve sheath diameter.
The purpose of this study is to compare Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in subjects with idiopathic intracranial hypertension and moderate-to-severe visual loss.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.